Finance

Lists
3692:HKG
Hansoh Pharmaceutical Group Company Ltd
HK$31,74
+1,15%
(+0,36) 1D
16 Okt., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 3692...
Open
HK$31,72
High
HK$32,44
Low
HK$31,52
Mkt. cap
192,48 mjd
Avg. vol.
8,58 m
Volume
10,50 m
Dividend
1,53%
Quarterly dividend
HK$0,12
Ex-dividend date
22 Sep. 2026
P/E ratio
24,51
52-wk high
HK$44,22
52-wk low
HK$28,06
EPS
HK$1,30
No. of employees
10 k
Open
HK$31,72
High
HK$32,44
Low
HK$31,52
Mkt. cap
192,48 mjd
Avg. vol.
8,58 m
Volume
10,50 m
Dividend
1,53%
Quarterly dividend
HK$0,12
Ex-dividend date
22 Sep. 2026
P/E ratio
24,51
52-wk high
HK$44,22
52-wk low
HK$28,06
EPS
HK$1,30
No. of employees
10 k
News stories
From web sources and news partners
Profile
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. Zhong and her family own 66% of the company. It is the largest psychotropic drug producer in China. Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange on 14 June 2019. In August 2022, it was announced that the company's stock would be added to the Hang Seng Index. Wikipedia
About Hansoh Pharmaceutical Group Company Ltd
CEO-
Employees9,64 k
Founded1995
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
3,80 mjd
3,80 mjd
4,15 mjd
4,15 mjd
Cost of goods sold
420,88 m
420,88 m
336,81 m
336,81 m
Cost of revenue
420,88 m
420,88 m
336,81 m
336,81 m
Research and development expenses
958,57 m
958,57 m
869,69 m
869,69 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,29 mjd
1,29 mjd
1,09 mjd
1,09 mjd
Operating expense
2,25 mjd
2,25 mjd
1,97 mjd
1,97 mjd
Total operating expenses
2,67 mjd
2,67 mjd
2,31 mjd
2,31 mjd
Operating income
1,12 mjd
1,12 mjd
1,84 mjd
1,84 mjd
Other non operating income
31,11 m
31,11 m
28,34 m
28,34 m
EBT including unusual items
1,43 mjd
1,43 mjd
2,50 mjd
2,50 mjd
EBT excluding unusual items
1,42 mjd
1,42 mjd
2,46 mjd
2,46 mjd
Income tax expense
220,95 m
220,95 m
375,70 m
375,70 m
Effective tax rate
15,44%
15,44%
15,00%
15,00%
Other operating expenses
6,65 m
6,65 m
9,48 m
9,48 m
Net income
1,21 mjd
1,21 mjd
2,13 mjd
2,13 mjd
Net profit margin
31,87%
31,87%
51,28%
51,28%
Earnings per share
-
-
-
-
Interest and investment income
284,14 m
284,14 m
630,79 m
630,79 m
Interest expense
-764,50 k
-764,50 k
-24,31 m
-24,31 m
Net interest expenses
283,37 m
283,37 m
606,48 m
606,48 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,21 mjd
1,21 mjd
1,93 mjd
1,93 mjd
Gain or loss from assets sale
-1,70 m
-1,70 m
-5,55 m
-5,55 m
AI content may include mistakes. Learn more
Google-programme